{
  "abstract": "The generalizability of FDA-cleared Lumipulse plasma pTau217 / A{beta}42 ratio cutpoints to Asian populations remains uncertain, especially in those with high burden of concomitant cerebrovascular disease (CeVD). We evaluated pTau217, A{beta}42 and their ratio in 205 Singapore-based participants with corresponding amyloid neuroimaging. In-house cutpoints were derived using a three-range strategy targeting 95% sensitivity and specificity. Plasma pTau217/A{beta}42 ratio outperformed pTau217 alone (area under the curve, 0.951 versus 0.925; p=0.004), with comparable performance across CeVD severities. Plasma ratio cutpoints achieved 98% negative predictive value, 88% positive predictive value, and 95% accuracy, classifying 10% as intermediate-risk. Using FDA-cleared cutpoints for our cohort retained 97% sensitivity and negative predictive value but yielded lower specificity (86%), positive predictive value (77%) and accuracy (85%), with 29% classified as intermediate-risk. Our findings support the need for population-specific validation of cutpoints from FDA-cleared blood biomarkers of brain amyloid pathology.",
  "abstract_shown": true,
  "affiliations": [
    "Yong Loo Lin School of Medicine, National University of Singapore"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "name": "J. R. Chong"
    },
    {
      "name": "A. T. Y. Yam"
    },
    {
      "name": "A. Toh"
    },
    {
      "name": "G. Jiang"
    },
    {
      "name": "T. Ito"
    },
    {
      "name": "C. Kobayashi"
    },
    {
      "name": "A. Dash"
    },
    {
      "name": "P. Sachdev"
    },
    {
      "name": "C. P. Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "M. K. Lai"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4cyh1fta84jre.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.11.04.26367313",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.11.04.26367313v1.full",
  "id": "4cyh1fta84jre",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.11.04.26367313v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "neurology"
    ]
  ],
  "openalex": null,
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.11.04.26367313v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-04",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4cyh1fta84jre.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T00:20:55Z",
      "native_id": "10.64898/2026.11.04.26367313",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.04.26367313v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:neurology",
      "subfield": "neurology"
    }
  ],
  "title": "Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden",
  "title_text": "Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden",
  "type": "preprint",
  "updated_at": "2026-11-08T00:20:57Z",
  "url": "https://research.draconitic.com/paper/4cyh1fta84jre",
  "venue": "medRxiv",
  "versions": []
}